Healthcare
from24/7 Wall St.
2 days agoXPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning
XPH provides broad, evenly weighted pharmaceutical exposure with limited concentration risk, focusing on drug developers and serving mainly as a portfolio diversifier.